Byung Won Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Byung Won Yoo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Jae Young Choi
Division of Pediatric Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
9 shared publications Jun Hee Sul
6 shared publications- Min Soo Park
Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
6 shared publications - Han Ki Park
Division of Cardiovascular Surgery, Department of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
5 shared publications - Young Hwan Park
Division of Cardiovascular Surgery, Department of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
5 shared publications - Choon Ok Kim
Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul 03722, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 45 (6) , 618-628
Estimating magnetic resonance imaging proton density fat fraction from ultrasound attenuation and clinical parameters in pediatric hepatic steatosis: development of a prediction model
Purpose: This study evaluated the diagnostic performance of the ultrasound-guided attenuation parameter (UGAP) for pediatric hepatic steatosis and developed a multivariable model to estimate magnetic resonance imaging proton density fat fraction (MRI-PDFF) from ultrasound and clinical variables.Methods: This single-center retrospective study included pediatric patients who underwent UGAP measurement and MRI-PDFF assessment within 3 months of each other. UGAP performance in detecting moderate-to-severe (≥S2) and severe (S3) steatosis was evaluated using the area under the receiver operating characteristic curve (AUC). Multivariable models were developed using linear regression and a random forest algorithm with five-fold cross-validation.Results: Among 45 patients (33 male and 12 female; median age, 12 years), median UGAP and MRI-PDFF values were 0.83 dB/cm/MHz and 22%, respectively. UGAP correlated moderately with MRI-PDFF (ρ=0.596, P<0.001). The AUC was 0.74 for both ≥S2 and S3 steatosis (95% confidence intervals [CIs], 0.58 to 0.91 and 0.60 to 0.89, respectively), and two discordant cases were identified. A model incorporating UGAP, age, height, and liver size outperformed UGAP alone in detecting ≥S2 steatosis (optimism-corrected AUC, 0.882 vs. 0.744; P=0.01). In the machine learning analysis, the model showed stable performance during cross-validation, with an AUC of 0.789 (95% CI, 0.649 to 0.928) for ≥S2 steatosis and an R² of 0.663 for continuous MRI-PDFF prediction.Conclusion: UGAP correlated moderately with MRI-PDFF and showed fair performance in grading pediatric hepatic steatosis. Combining UGAP with clinical parameters significantly improved MRI-PDFF estimation, providing a practical screening tool for hepatic steatosis when MRI is unavailable. External validation is needed.
- 1 November 2026
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 45 (6) , 618-628
Open AccessEstimating magnetic resonance imaging proton density fat fraction from ultrasound attenuation and clinical parameters in pediatric hepatic steatosis: development of a prediction model
Purpose: This study evaluated the diagnostic performance of the ultrasound-guided attenuation parameter (UGAP) for pediatric hepatic steatosis and developed a multivariable model to estimate magnetic resonance imaging proton density fat fraction (MRI-PDFF) from ultrasound and clinical variables.Methods: This single-center retrospective study included pediatric patients who underwent UGAP measurement and MRI-PDFF assessment within 3 months of each other. UGAP performance in detecting moderate-to-severe (≥S2) and severe (S3) steatosis was evaluated using the area under the receiver operating characteristic curve (AUC). Multivariable models were developed using linear regression and a random forest algorithm with five-fold cross-validation.Results: Among 45 patients (33 male and 12 female; median age, 12 years), median UGAP and MRI-PDFF values were 0.83 dB/cm/MHz and 22%, respectively. UGAP correlated moderately with MRI-PDFF (ρ=0.596, P<0.001). The AUC was 0.74 for both ≥S2 and S3 steatosis (95% confidence intervals [CIs], 0.58 to 0.91 and 0.60 to 0.89, respectively), and two discordant cases were identified. A model incorporating UGAP, age, height, and liver size outperformed UGAP alone in detecting ≥S2 steatosis (optimism-corrected AUC, 0.882 vs. 0.744; P=0.01). In the machine learning analysis, the model showed stable performance during cross-validation, with an AUC of 0.789 (95% CI, 0.649 to 0.928) for ≥S2 steatosis and an R² of 0.663 for continuous MRI-PDFF prediction.Conclusion: UGAP correlated moderately with MRI-PDFF and showed fair performance in grading pediatric hepatic steatosis. Combining UGAP with clinical parameters significantly improved MRI-PDFF estimation, providing a practical screening tool for hepatic steatosis when MRI is unavailable. External validation is needed.
- Open Access
- 10 December 2025
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 68 (12) , 857-867
Comprehension and practical considerations in pediatric pharmacotherapy: a narrative review
Purpose: Pediatric pharmacotherapy requires a thorough understanding of developmental physiology and the distinct pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of this population. Unlike adults, children (particularly neonates and infants) exhibit substantial differences in drug absorption, distribution, metabolism, and excretion as a result of immature organ function and rapid developmental changes. These characteristics must be considered for safety and efficacy in pediatric pharmacotherapy.Current Concepts: PK differences in children arise from development-dependent factors, including an altered intestinal environment, higher total body water content, immature drug-metabolizing enzyme systems, reduced plasma protein quantity and drug-binding capacity, and limited renal clearance. PD variability relates to age-specific receptor sensitivity and differences in drug response across developmental stages. In addition, children (particularly those younger than 1 year) are more susceptible to adverse drug reactions because of developmental vulnerabilities and the frequent use of off-label medications.Discussion and Conclusion: Optimal pediatric dosing should consider not only chronological age and body weight, but also the maturation of organ systems and metabolic pathways. Practical considerations, including appropriate routes of administration and suitable food vehicles, should be selected according to the child’s developmental pharmacological status. Although regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency actively encourage pediatric clinical studies, approved pediatric dosing information remains limited. Therefore, clinicians must rely on fundamental principles of developmental pharmacology and available evidence-based guidelines. A comprehensive understanding of developmental pharmacology, individualized dose adjustment based on developmental PK status, and vigilant monitoring for adverse effects are essential for safe and effective pediatric pharmacotherapy.
- 10 December 2025
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 68 (12) , 857-867
Open AccessComprehension and practical considerations in pediatric pharmacotherapy: a narrative review
Purpose: Pediatric pharmacotherapy requires a thorough understanding of developmental physiology and the distinct pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of this population. Unlike adults, children (particularly neonates and infants) exhibit substantial differences in drug absorption, distribution, metabolism, and excretion as a result of immature organ function and rapid developmental changes. These characteristics must be considered for safety and efficacy in pediatric pharmacotherapy.Current Concepts: PK differences in children arise from development-dependent factors, including an altered intestinal environment, higher total body water content, immature drug-metabolizing enzyme systems, reduced plasma protein quantity and drug-binding capacity, and limited renal clearance. PD variability relates to age-specific receptor sensitivity and differences in drug response across developmental stages. In addition, children (particularly those younger than 1 year) are more susceptible to adverse drug reactions because of developmental vulnerabilities and the frequent use of off-label medications.Discussion and Conclusion: Optimal pediatric dosing should consider not only chronological age and body weight, but also the maturation of organ systems and metabolic pathways. Practical considerations, including appropriate routes of administration and suitable food vehicles, should be selected according to the child’s developmental pharmacological status. Although regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency actively encourage pediatric clinical studies, approved pediatric dosing information remains limited. Therefore, clinicians must rely on fundamental principles of developmental pharmacology and available evidence-based guidelines. A comprehensive understanding of developmental pharmacology, individualized dose adjustment based on developmental PK status, and vigilant monitoring for adverse effects are essential for safe and effective pediatric pharmacotherapy.
- Open Access
- 21 October 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (10) , e70032
Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
Izuforant is a selective, and potent histamine H4 receptor (H4R) antagonist developed to treat atopic dermatitis (AD). There is an unmet medical need for therapeutic agents to control inflammation and pruritus. Izuforant is a strong candidate for this task based on the findings of non‐clinical studies showing that inhibition of the histamine‐mediated signaling pathway via H4R by izuforant results in decreased pruritus and inflammation. This study aimed to evaluate the clinical pharmacokinetic (PK) and pharmacodynamic (PD) profiles of izuforant. Dose‐block‐randomized, double‐blind, placebo‐controlled, single‐ and multiple ascending dose studies were conducted in 64 healthy volunteers. For the single ascending dose (SAD) study, 10–600 mg izuforant was administered to the designated groups. For the multiple ascending dose (MAD) study, 100–400 mg izuforant was administered to three groups. The clinical pharmacokinetic (PK) profile of izuforant was evaluated using plasma and urine concentrations. Blood sampling for the PD assay, which measured imetit‐induced eosinophil shape changes (ESC), was also conducted. A one‐compartment PK model described the distribution and elimination profiles of izuforant. An imetit‐induced ESC inhibition test was established and validated for PD evaluation as a measure of the H4R antagonistic effect. ESC inhibition was observed even at doses as low as 10 mg; however, this inhibition became stronger and lasted longer as the dose increased. All izuforant doses were well tolerated, and no discontinuations due to adverse events (AE) or deaths were reported.
- 21 October 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (10) , e70032
Open AccessPharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
Izuforant is a selective, and potent histamine H4 receptor (H4R) antagonist developed to treat atopic dermatitis (AD). There is an unmet medical need for therapeutic agents to control inflammation and pruritus. Izuforant is a strong candidate for this task based on the findings of non‐clinical studies showing that inhibition of the histamine‐mediated signaling pathway via H4R by izuforant results in decreased pruritus and inflammation. This study aimed to evaluate the clinical pharmacokinetic (PK) and pharmacodynamic (PD) profiles of izuforant. Dose‐block‐randomized, double‐blind, placebo‐controlled, single‐ and multiple ascending dose studies were conducted in 64 healthy volunteers. For the single ascending dose (SAD) study, 10–600 mg izuforant was administered to the designated groups. For the multiple ascending dose (MAD) study, 100–400 mg izuforant was administered to three groups. The clinical pharmacokinetic (PK) profile of izuforant was evaluated using plasma and urine concentrations. Blood sampling for the PD assay, which measured imetit‐induced eosinophil shape changes (ESC), was also conducted. A one‐compartment PK model described the distribution and elimination profiles of izuforant. An imetit‐induced ESC inhibition test was established and validated for PD evaluation as a measure of the H4R antagonistic effect. ESC inhibition was observed even at doses as low as 10 mg; however, this inhibition became stronger and lasted longer as the dose increased. All izuforant doses were well tolerated, and no discontinuations due to adverse events (AE) or deaths were reported.
- Open Access
- 31 December 2023
- Published by Korean Society of Kawasaki Disease in Kawasaki Disease
- Vol. 1 (2)
Antithrombotic Therapy in Kawasaki Disease
Kawasaki disease is an acute systemic vasculitis and leads to a hypercoagulable state caused by marked elevation of the platelet count, platelet activation, and endothelial dysfunction. Therefore, anti-inflammatory and antithrombotic therapy using intravenous immunoglobulin and aspirin is recommended as an initial treatment, although the debate on the efficacy and dosage of aspirin is still ongoing. Antithrombotic therapy is crucial in patients with coronary aneurysms because thrombosis is promoted in the acute and chronic phase of the disease and coronary thrombosis leads to fatal results. All the platelets, vascular endothelium, and clotting factors are involved in thrombosis in coronary aneurysms, thus combination therapy of antiplatelet and anticoagulant agents is essential. Generally, patients with giant aneurysms are recommended a combination of low-dose aspirin and warfarin regardless of coronary artery stenosis. In patients with an extraordinarily high risk of thrombosis, who have rapidly expanding coronary aneurysms or a recent history of coronary artery thrombosis, low molecular weight heparin (LMWH) instead of warfarin or triple therapy consisting of low-dose aspirin, clopidogrel, and warfarin can be considered. New drugs such as direct oral anticoagulants (DOACs) and abciximab are introduced in patients with Kawasaki disease, but further evidence on these patients is needed.
- 31 December 2023
- Published by Korean Society of Kawasaki Disease in Kawasaki Disease
- Vol. 1 (2)
Open AccessAntithrombotic Therapy in Kawasaki Disease
Kawasaki disease is an acute systemic vasculitis and leads to a hypercoagulable state caused by marked elevation of the platelet count, platelet activation, and endothelial dysfunction. Therefore, anti-inflammatory and antithrombotic therapy using intravenous immunoglobulin and aspirin is recommended as an initial treatment, although the debate on the efficacy and dosage of aspirin is still ongoing. Antithrombotic therapy is crucial in patients with coronary aneurysms because thrombosis is promoted in the acute and chronic phase of the disease and coronary thrombosis leads to fatal results. All the platelets, vascular endothelium, and clotting factors are involved in thrombosis in coronary aneurysms, thus combination therapy of antiplatelet and anticoagulant agents is essential. Generally, patients with giant aneurysms are recommended a combination of low-dose aspirin and warfarin regardless of coronary artery stenosis. In patients with an extraordinarily high risk of thrombosis, who have rapidly expanding coronary aneurysms or a recent history of coronary artery thrombosis, low molecular weight heparin (LMWH) instead of warfarin or triple therapy consisting of low-dose aspirin, clopidogrel, and warfarin can be considered. New drugs such as direct oral anticoagulants (DOACs) and abciximab are introduced in patients with Kawasaki disease, but further evidence on these patients is needed.
- Open Access
- 21 June 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (8) , 1469-1478
Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
Evogliptin (EV) is a novel dipeptidyl peptidase 4 inhibitor (DPP4i) for glycemic control in patients with type 2 diabetes mellitus (T2DM). This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV and sodium glucose cotransporter- 2 inhibitors (SGLT2i) in healthy volunteers since combination therapy of DPP4i and SGLT2i has been considered as an effective option for T2DM treatment. A randomized, open-label, multiple dose, two arm, three-period, three treatments, two-sequence crossover study was conducted in healthy Korean volunteers. In arm 1, subjects were administered 5 mg of EV once daily for 7 days, 25 mg of empagliflozin (EP) once daily for 5 days, and the combination once daily for 5 days (EV + EP). In arm 2, subjects were administered 5 mg of EV once daily for 7 days, 10 mg of dapagliflozin (DP) once daily for 5 days, and the combination once daily for 5 days (EV + DP). Serial blood samples were collected for PK analysis, and oral glucose tolerance tests were conducted for PD analysis. In each arm, a total of 18 subjects completed the study. All adverse events (AEs) were mild with no serious AEs. The geometric mean ratio and confidence interval of the main PK parameters (maximum concentration of the drug in plasma at steady state and area under the plasma drug concentration time curve within a dosing interval at a steady state) between EV and either EP or DP alone were not significantly altered by co-administration. Administration of EV + EP or EV + DP did not result in significant PD changes, as determined by the glucose-lowering effect. Administration of EV + EP or EV + DP had no significant effects on the PK profiles of each drug. All treatments were well-tolerated.
- 21 June 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (8) , 1469-1478
Open AccessPharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
Evogliptin (EV) is a novel dipeptidyl peptidase 4 inhibitor (DPP4i) for glycemic control in patients with type 2 diabetes mellitus (T2DM). This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV and sodium glucose cotransporter- 2 inhibitors (SGLT2i) in healthy volunteers since combination therapy of DPP4i and SGLT2i has been considered as an effective option for T2DM treatment. A randomized, open-label, multiple dose, two arm, three-period, three treatments, two-sequence crossover study was conducted in healthy Korean volunteers. In arm 1, subjects were administered 5 mg of EV once daily for 7 days, 25 mg of empagliflozin (EP) once daily for 5 days, and the combination once daily for 5 days (EV + EP). In arm 2, subjects were administered 5 mg of EV once daily for 7 days, 10 mg of dapagliflozin (DP) once daily for 5 days, and the combination once daily for 5 days (EV + DP). Serial blood samples were collected for PK analysis, and oral glucose tolerance tests were conducted for PD analysis. In each arm, a total of 18 subjects completed the study. All adverse events (AEs) were mild with no serious AEs. The geometric mean ratio and confidence interval of the main PK parameters (maximum concentration of the drug in plasma at steady state and area under the plasma drug concentration time curve within a dosing interval at a steady state) between EV and either EP or DP alone were not significantly altered by co-administration. Administration of EV + EP or EV + DP did not result in significant PD changes, as determined by the glucose-lowering effect. Administration of EV + EP or EV + DP had no significant effects on the PK profiles of each drug. All treatments were well-tolerated.
- Open Access
- 1 September 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 3151-3159
The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
Background: Esomeprazole is the most effective treatment for acid-related disorders and is widely used with enteric coating due to rapid degradation in the acidic environment. However, the enteric-coated formulation delays absorption and onset of action. To overcome this limitation, an immediate-release formulation containing esomeprazole 20 mg and sodium bicarbonate 800 mg (IR-ESO) was developed. Purpose: To evaluate the safety, pharmacokinetics (PK), and pharmacodynamics of IR-ESO compared to those of esomeprazole 20 mg (ESO). Methods: A randomized, open-label, multiple-dose, two-treatment, two-sequence crossover study was conducted in 40 healthy male subjects. Subjects received either IR-ESO or ESO for 7 days. After single and multiple dosing, blood samples were collected for PK analysis, and intragastric pH was assessed by 24-hr pH monitoring. Results: Plasma esomeprazole exposure of IR-ESO was similar to that of ESO after single and multiple dosing. Time to peak concentration of IR-ESO (0.50–0.75 hr) was shorter than that of ESO (1.25–1.50 hr). Percentage changes in 24-hr integrated gastric acidity from baseline for IR-ESO were similar to those for ESO. In addition, mean time to maintain gastric pH >4 for 24 hr was similar for both drugs (IR-ESO 55.5–69.9% vs ESO 56.8–70.2%). Evaluation of time to first reach pH 4 after dosing indicated that IR-ESO showed a faster onset than ESO. All subjects found the drug tolerable, and there were no significant differences in adverse events between two drugs. Conclusion: This study showed that IR-ESO produced a rapid, safe and sustained gastric acid suppression (ClinicalTrials.gov: NCT03211143).
- 1 September 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 3151-3159
Open AccessThe safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
Background: Esomeprazole is the most effective treatment for acid-related disorders and is widely used with enteric coating due to rapid degradation in the acidic environment. However, the enteric-coated formulation delays absorption and onset of action. To overcome this limitation, an immediate-release formulation containing esomeprazole 20 mg and sodium bicarbonate 800 mg (IR-ESO) was developed. Purpose: To evaluate the safety, pharmacokinetics (PK), and pharmacodynamics of IR-ESO compared to those of esomeprazole 20 mg (ESO). Methods: A randomized, open-label, multiple-dose, two-treatment, two-sequence crossover study was conducted in 40 healthy male subjects. Subjects received either IR-ESO or ESO for 7 days. After single and multiple dosing, blood samples were collected for PK analysis, and intragastric pH was assessed by 24-hr pH monitoring. Results: Plasma esomeprazole exposure of IR-ESO was similar to that of ESO after single and multiple dosing. Time to peak concentration of IR-ESO (0.50–0.75 hr) was shorter than that of ESO (1.25–1.50 hr). Percentage changes in 24-hr integrated gastric acidity from baseline for IR-ESO were similar to those for ESO. In addition, mean time to maintain gastric pH >4 for 24 hr was similar for both drugs (IR-ESO 55.5–69.9% vs ESO 56.8–70.2%). Evaluation of time to first reach pH 4 after dosing indicated that IR-ESO showed a faster onset than ESO. All subjects found the drug tolerable, and there were no significant differences in adverse events between two drugs. Conclusion: This study showed that IR-ESO produced a rapid, safe and sustained gastric acid suppression (ClinicalTrials.gov: NCT03211143).
- Open Access
- 1 January 2019
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 49 (1) , 109-112
New Insight to the Pathogenetic Mechanism of Kawasaki Disease (KD): the Relationship between Clinical Diversity and Genetic Heterogeneity
Yoo BW. Korean Circ J. 2018 Aug;49:e16. https://doi.org/10.4070/kcj.2018.0365
- 1 January 2019
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 49 (1) , 109-112
Open AccessNew Insight to the Pathogenetic Mechanism of Kawasaki Disease (KD): the Relationship between Clinical Diversity and Genetic Heterogeneity
Yoo BW. Korean Circ J. 2018 Aug;49:e16. https://doi.org/10.4070/kcj.2018.0365
- Open Access
- 1 August 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2381-2387
Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
Purpose: Filgrastim, a granulocyte-colony stimulating factor, is used to treat patients with neutropenia, including neutropenic fever. Leucostim® is a recombinant filgrastim product tested for biosimilarity with its reference product, Neupogen®. We conducted a comparative clinical trial of the 2 products. Patients and methods: A randomized, open-label, 2-way crossover, single-dose Phase I study was conducted for 56 healthy subjects. After a 5 and 10 μg/kg single subcutaneous administration of test and reference product, pharmacokinetic and pharmacodynamic parameters (absolute neutrophil count and CD34+ cell count) were compared. During the study, safety tests and adverse event monitoring were performed. Results: The test and the reference products had a comparable pharmacokinetic, pharmacodynamic, and safety profile. In both 5 and 10 μg/kg dosing, the 90% CIs of the test to reference ratio for primary parameters (peak plasma concentration and area under the plasma concentration vs time curve from time 0 extrapolated to the infinite time for plasma filgrastim concentration; maximal effect and area under the time-effect curve from time 0 to time of the last quantifiable effect for absolute neutrophil count) were within the 0.8–1.25 range. In addition, safety profiles between the 2 products were similar without any serious adverse events. Conclusion: This study has provided firm clinical evidence that the test filgrastim product is similar to its reference filgrastim product.
- 1 August 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2381-2387
Open AccessComparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
Purpose: Filgrastim, a granulocyte-colony stimulating factor, is used to treat patients with neutropenia, including neutropenic fever. Leucostim® is a recombinant filgrastim product tested for biosimilarity with its reference product, Neupogen®. We conducted a comparative clinical trial of the 2 products. Patients and methods: A randomized, open-label, 2-way crossover, single-dose Phase I study was conducted for 56 healthy subjects. After a 5 and 10 μg/kg single subcutaneous administration of test and reference product, pharmacokinetic and pharmacodynamic parameters (absolute neutrophil count and CD34+ cell count) were compared. During the study, safety tests and adverse event monitoring were performed. Results: The test and the reference products had a comparable pharmacokinetic, pharmacodynamic, and safety profile. In both 5 and 10 μg/kg dosing, the 90% CIs of the test to reference ratio for primary parameters (peak plasma concentration and area under the plasma concentration vs time curve from time 0 extrapolated to the infinite time for plasma filgrastim concentration; maximal effect and area under the time-effect curve from time 0 to time of the last quantifiable effect for absolute neutrophil count) were within the 0.8–1.25 range. In addition, safety profiles between the 2 products were similar without any serious adverse events. Conclusion: This study has provided firm clinical evidence that the test filgrastim product is similar to its reference filgrastim product.
- 27 July 2018
- Published by Springer Nature
- Vol. 1065, 49-59
Epidemiology of Congenital Heart Disease with Emphasis on Sex-Related Aspects
Gender differences in prevalence, manifestation, treatment outcomes, and prognosis have been well known for acquired heart disease such as coronary artery disease. Regarding congenital heart disease (CHD), it is recognized that the incidence of each congenital heart defect varies according to sex observed during a time span of more than 40 years. As diagnostic and surgical methods for CHD have achieved dramatic advances for the past decades, more newborns with CHD were able to survive and reach adulthood. Thereafter gender differences have begun to be reported on mortality, progress to pulmonary arterial hypertension, treatment outcomes, and prognosis in patients with CHD. However, it has been less known in the field of CHD yet, and this contribution describes information that is relatively well studied to date.
- 27 July 2018
- Published by Springer Nature
- Vol. 1065, 49-59
Epidemiology of Congenital Heart Disease with Emphasis on Sex-Related Aspects
Gender differences in prevalence, manifestation, treatment outcomes, and prognosis have been well known for acquired heart disease such as coronary artery disease. Regarding congenital heart disease (CHD), it is recognized that the incidence of each congenital heart defect varies according to sex observed during a time span of more than 40 years. As diagnostic and surgical methods for CHD have achieved dramatic advances for the past decades, more newborns with CHD were able to survive and reach adulthood. Thereafter gender differences have begun to be reported on mortality, progress to pulmonary arterial hypertension, treatment outcomes, and prognosis in patients with CHD. However, it has been less known in the field of CHD yet, and this contribution describes information that is relatively well studied to date.
- Open Access
- 30 May 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (9) , 1149-1157
Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study
Ilaprazole, the latest proton pump inhibitor, can be used with clarithromycin and amoxicillin as a triple therapy regimen for eradicating Helicobacter pylori. The aim of this study was to evaluate pharmacokinetic drug interactions and safety profiles after coadministration of clarithromycin, amoxicillin, and ilaprazole.
- 30 May 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (9) , 1149-1157
Open AccessPharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study
Ilaprazole, the latest proton pump inhibitor, can be used with clarithromycin and amoxicillin as a triple therapy regimen for eradicating Helicobacter pylori. The aim of this study was to evaluate pharmacokinetic drug interactions and safety profiles after coadministration of clarithromycin, amoxicillin, and ilaprazole.